← All trials
NCT06517914
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 29, 2024
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2026
- First posted
- Jul 24, 2024
- Last posted
- Aug 1, 2024
- Enrollment
- 108
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yuhan Pharmaceutical CompanyLead sponsor
- Cha Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.